Samrat Pharmachem Ltd. – Company Report
1. Company Overview
Samrat Pharmachem Ltd., incorporated in 1992 and headquartered in Ankleshwar, Gujarat, is a specialist manufacturer of iodine derivatives and select bromine salts, catering to a wide range of industries including pharmaceuticals, animal feed, fertilizers, food, chemicals, and textiles. It is recognized as one of the largest Indian manufacturers and exporters of iodine-based chemicals, with a strong global customer base and regulatory compliance.
The company's facility in Ankleshwar features advanced multi-product manufacturing lines supported by robust in-house R&D. Samrat Pharmachem is publicly listed on BSE and operates a modern corporate office in Mumbai.
Key Highlights
- Incorporated: 1992
- Headquarters: Ankleshwar, Gujarat, India
- Employees: 51–200
- Certifications: ISO 9001; facilities approved by USFDA, EU-GMP, MHRA, and other global agencies
- Product Focus: Iodine derivatives, select bromine salts
- Major End Users: Pharmaceuticals, animal feed, food, salt, fertilizers, chemicals, textiles
- Export Reach: USA, Europe, Africa, Asia, Middle East
- Listing: BSE; Market Cap (Aug 2025): ~₹107 crore
- Promoters: Mehta family (Lalit Mehta and Rajesh Mehta)
- Competitive Edge: India’s broadest iodine derivative portfolio, strong R&D, long-standing export clients
2. Products and Services
- Iodine Derivatives: Potassium iodide, sodium iodide, ethyl iodide, propyl iodide, and a variety of custom iodine-based compounds
- Bromine Derivatives: Ammonium bromide, sodium bromide, and other selected chemicals
- Custom Synthesis: Specialty ingredients and intermediates tailored for global life sciences and pharmaceutical players
- Industries Served: APIs, intermediates, FMCG, technical, fertilizer, animal feed, textile, food, and chemical sectors
- R&D & Regulatory Support: In-house iodine chemistry expertise with global regulatory filing support
3. Recent News and Business Developments (2025)
- Board Reshuffling: New independent director appointed (July 2025); multiple changes in board composition during June–July 2025
- Regulatory Filings: Compliance with SEBI and share depository regulations; not classified as a SEBI large corporate
- Capacity & Margin Focus: Company pursuing capacity enhancement and margin recovery initiatives
- Leadership Continuity: Management re-appointed for a 5-year term starting April 2026 (pending shareholder approval)
- FII Exit: Foreign institutional holdings reduced to zero by June 2025
4. Financial Performance (FY2025)
| Metric | FY2025 Value |
|---|---|
| Revenue from Operations | ₹286 crore |
| Net Profit (PAT) | ₹7.11 crore |
| Operating Profit | ₹10 crore |
| Operating Profit Margin | 4% |
| Earnings Per Share (EPS) | ₹23.01 |
| Dividend Payout % | 4% |